Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct.
[3] Once an intraductal papillary mucinous neoplasm has been found, the management options include close monitoring and pre-emptive surgery.
[5] By histopathology, IPMN is characterized on light microscopy by Mucinous epithelial cells,[6] and growth within the pancreatic ducts.
A study using Surveillance, Epidemiology, and End Results Registry (SEER) data suggested that increased lymph node counts harvested during the surgery were associated with better survival in invasive IPMN patients.
In 1982, IPMN was reported as a "mucin-producing tumor" by Kazuhiko Ohashi of the Japanese Foundation for Cancer Research.
Histopathology of IPMN types in a distal pancreatectomy specimen from a 60-year-old man, by gross pathology (center image), microscopy and
immunohistochemistry
: The resected specimen (c) revealed that the mural nodule in the MPD consisted of PB-type IPMN with high-grade dysplasia (adenocarcinoma) (a) with a diffuse positivity of p53 immunostaining (an insert) and KRAS mutation (G12V). The BD-IPMN of the body was lined by gastric mucinous epithelium showing low papillary configuration with mild epithelial stratification with the same KRAS mutation (d), and the proliferation of similar gastric IPMN components sequentially involved the bottom of the mural nodule and the wall of the surrounding dilated MPD (indicated by red arrowheads) (b). The BD-IPMN of the tail was lined by flat, monolayer gastric mucinous epithelium lacking cellular atypia and KRAS mutation (e).
[
4
]
Relative incidences of various pancreatic neoplasms, with intraductal papillary mucinous neoplasm annotated at center right.
[
17
]
